Stability of Captopril in SyrSPend SF

Geiger, Christine M; Sorenson, Bridget; Whaley, Paul A

Abstract

Stability of Captopril in SyrSPend SF

Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A

Issue: Jul/Aug 2013 - Volume 17, Number 4

View All Articles in Issue

Page(s): 336-338

Download in electronic PDF format for $75

Abstract

Captopril is an angiotensin-converting enzyme inhibitor available as a tablet. Patients who are unable to take tablets have led compounding pharmacies to seek alternative dosage forms including solutions and suspensions. The objective of this study was to determine the stability of captopril in sorbitol-free, alcohol-free SyrSpend SF suspending agent. The studied samples were compounded into a 0.8-mg/mL suspension and stored in low-actinic plastic bottles at temperatures between 2°C to 8°C. Six samples were assayed at each time point out to 32 days by a stability- indicating high-performance liquid chromatography method. The samples remained within 90% to 110% of the initial concentration throughout day 14 of the study. Based on the data collected, the beyond-use date of these preparations is 14 days when protected from light and refrigerated.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2013 Pg. 336-338	Stability of Captopril in SyrSPend SF Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
Mar/Apr 2019 Pg. 148	Captopril 0.8 mg/mL in SyrSpend SF Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 2013 Pg. 344-346	Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul A
May/Jun 2004 Pg. 223-227	Quality-Control Analytical Methods: High-Performance Liquid Chromatography Author(s): Kupiec Thomas C
May/Jun 2003 Pg. 170-174	Five Compounds for Treating Diabetes-Related Conditions Author(s): Meece Jerry
Mar/Apr 2016 Pg. 167-174	Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions Author(s): Polonini HC, Loures S, Lima LC, Ferreira AO, Brandão MA
Mar/Apr 2017 Pg. 164-170	Development and Application of a High-Performance Liquid Chromatography Stability-Indicating Assay for Beyond-Use Date Determination of Compounded Topical Gels Containing Multiple Active Drugs Author(s): Gorman Gregory, Sokom Simara, Coward Lori, Arnold John J
Nov/Dec 2018 Pg. 494	Enalapril Maleate 1 mg/mL in SyrSpend SF pH4 Oral Suspension Author(s): Allen Loyd V Jr
Jul/Aug 1999 Pg. 314-315	Quantitation of Testosterone-Cypionate-in-Oil Injection using High Performance Liquid Chromatography Author(s): Gupta Vishnu D, Pramar Y
Mar/Apr 1999 Pg. 158-159	Quantitation of Testosterone Propionate in an Injection Using High Performance Liquid Chromatography Author(s): Gupta Vishnu D
Jul/Aug 2017 Pg. 322-329	Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2017 Pg. 339-346	Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4 Author(s): de Oliveira Ferreira Anderson, Polonini Hudson, Loures da Silva Sharlene, Buzinari Aglio Natália Cristina, Abreu Jordana, Fernandes Brandão Marcos Antônio
Sep/Oct 2014 Pg. 427-431	Physicochemical and Microbiological Stabilities of Hydrocortisone in InOrpha Suspending Agent Studied Under Various Condition Author(s): Bourget Philippe, Amin Alexandre, Vidal Fabrice, Pieyre Manon, Dosso El Ourmar, Beauvais Raphaelle, Loeuillet Richard
Nov/Dec 2014 Pg. 456-460	Standards of Practice, Professional Judgment, and Scientific Evidence to Establish and Extend a Beyond-Use Date Author(s): Thomson Cassandra Marie, Savji Taslim
Mar/Apr 2011 Pg. 124-128	Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease Author(s): Corsini Lindsay, Williams LaVonn A
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Sep/Oct 2015 Pg. 420-427	Stability Assessment of 10 Active Pharmaceutical Ingredients Compounded in SyrSpend SF Author(s): Geiger Christine M, Sorenson Bridget, Whaley Paul
Jul/Aug 2020 Pg. 318	Lisinopril 1 mg/mL in SyrSpend SF pH4 Author(s): Allen Loyd V Jr
Jul/Aug 2020 Pg. 327-336	Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4 Author(s): Espana B, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2017 Pg. 334-338	Stability of Spironolactone Oral Suspension in PCCA Base, SuspendIt Author(s): Graves Richard, Phan Kelly V, Bostanian Levon A, Mandal Tarun K, Pramar Yashoda V